SyVento and OncoArendi have signed a joint development collaboration and exclusive global licensing agreement for the use of the nanoliposomal formulation of the arginase inhibitor OATD-02.
Details in following press release.
April 28, 2025
SyVento BioTech at BIO Korea 2025We are excited to announce that SyVento BioTech will be participating in BIO Korea 2025, one of Asia’s premier biotechnology and pharmaceutical events, taking place 7–9 May in Seoul. Our company will be proudly represented by Eliza Milewicz, Member of the Supervisory Board, who will be engaging in one-on-one partnering meetings, exploring collaborative opportunities, and […]